Nereus Pharmaceuticals, Inc.

Other

Barbara Christine Potts

Rama Manam

Katherine A McArthur

Ta-Hsiang Chao

Kin S Lam

Saskia Theodora Cornelia Neuteboom

Scott Sherman Mitchell

Venkat Rami Reddy Macherla

Venkata Rami Reddy Macherla

Katherine Anne Reed

Benjamin Nicholson

Jennifer Grodberg

Ginger Tsueng

Taotao Ling

Donald J White

Venkat Macherla

Ram Rao Manam

Saskia Neuteboom

Cheryl L Billstrom

Michael A Palladino

Jan-Jon Chu

Natasha Reddinger

Cheryl (Billstrom) Sifferlen

Bao Viet Mai

Ramsharan Singh

Saskia Theodora Neuteboom

Venkata Rami Macherla

Rama Rao Manam

Katherine Mcarthur

Disclosed herein are compounds of Formula (I) that include a sulfonate ester, ester or ether group. Compounds of Formula (I) can be included in pharmaceutical compositions, and can be used to treating and/or ameliorating a disease or condition, such as cancer, a microbial disease and/or inflammation.

Proteasome inhibitors

The present invention relates to certain compounds and to methods for the preparation of certain compounds that can be used in the fields of chemistry and medicine. Specifically, described herein are methods for the preparation of various compounds and intermediates, and the compounds and intermediates themselves. More specifically, described herein are methods for synthesizing Salinosporamide A and its analogs from a compound of formula (V). 

Total synthesis of salinosporamide A and analogs thereof

Lyophilized formulations comprising Salinosporamide A or analogs thereof are provided. In some aspects, lyophilized formulations comprising Salinosporamide A or analogs thereof and bulking agents are provided. Also provided are methods of lyophilizing Salinosporamide A or analogs thereof. In some aspects, a solvent or co-solvent system is utilized. Also provided are methods of administering Salinosporamide A or analogs thereof to patients.

Lyophilized formulations of Salinosporamide A

Disclosed are methods of treating cancer comprising administering to the animal, a therapeutically effective amount of a heterocyclic compound of Formula VI. The animal is a mammal, preferably a human or a rodent.

Methods of using [3.2.0] heterocyclic compounds and analogs thereof

Compounds of Formulae I-VI and derivatives thereof having anti-cancer, anti-inflammatory, and anti-microbial properties and to compositions that include one or more of compounds and their derivatives or analogs having anti-cancer, anti-inflammatory and anti-microbial properties are disclosed. Pharmaceutical compositions comprising such compounds and methods of treating cancer, inflammatory conditions, and microbial infections with the disclosed compounds or the disclosed pharmaceutical compositions are also disclosed.

[3.2.0] Heterocyclic compounds and methods of using the same

Compounds of Formula I, commonly referred to as bis-indole pyrroles, including isolated naturally-occurring compounds, synthetic and semi-synthetic derivatives thereof having antimicrobial properties and to antimicrobial compositions that include one or more of bis-indole pyrroles and their derivatives or analogs having antimicrobial properties are disclosed. Pharmaceutical compositions comprising such compounds and methods of treating bacterial infections with the disclosed compounds or the disclosed pharmaceutical compositions are also disclosed.

Bis-indole pyrroles useful as antimicrobials agents

Disclosed herein are novel spiro beta-lactone/gamma lactams for use in treating bacterial infections and cancer. The compounds are characterized by a terminal electron-withdrawing group such as a nitro group. Screening data shows antimicrobial activity against various bacterial cell lines, particularly gram-positive bacteria, and anti-cancer activity.

Anti-bacterial and anti-cancer spiro beta-lactone/gamma-lactams

Growing community of inventors

Escondido, CA, United States of America

Barbara Christine Potts